Altimmune, Inc.
A clinical-stage biopharmaceutical company developing pemvidutide, a balanced GLP-1 and glucagon dual receptor agonist in late-stage trials for fatty-liver disease (MASH), alcohol use disorder, and alcohol-associated liver disease. It began in 1997 as vaccine maker Vaxin Inc. before renaming to Altimmune in 2015, and its early work included NasoVAX, a needle-free intranasal flu vaccine.
Granted 295.5K
Granted 124.6K
Granted 69.7K
Granted 87.7K
Granted 41.8K · Sold 16.0K
Bought 47.5K
Granted 26.4K
Granted 18.8K · Bought 25.0K
Bought 21.7K
Bought 5.0K
Granted 1.3K
Bought 1.5K
Bought 527
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Garg Vipin KDirector · 23 transactions | +70.3% | 424.5K | 295.5K | — | — |
| Roberts M ScotChief Scientific Officer · 27 transactions | +452.4% | 112.8K | 124.6K | — | — |
| Harris Matthew ScottChief Medical Officer · 19 transactions | — | 83.9Kas of Aug 2025 | 69.7K | — | — |
| Jordt Raymond MChief Business Officer · 17 transactions | +3726.8% | 70.1K | 87.7K | — | — |
| Drutz DavidDirector · 4 transactions | +86.4% | 55.5Kas of Aug 2024 | 41.8K | — | 16.0K |
| Durso Jerome BenedictPresident and CEO, Director · 3 transactions | — | 47.5K | — | 47.5K | — |
| Eisenstadt Richard IChief Financial Officer · 5 transactions | +88.8% | 45.0Kas of Jan 2024 | 26.4K | — | — |
| Weaver Gregory LChief Financial Officer · 5 transactions | — | 38.1K | 18.8K | 25.0K | — |
| Gill JohnDirector · 2 transactions | +683.1% | 21.7K | — | 21.7K | — |
| Pisano WayneDirector · 1 transaction | +58.8% | 13.5K | — | 5.0K | — |
| Shutterly AndrewActing Chief Financial Officer · 1 transaction | — | 11.4Kas of Jul 2024 | 1.3K | — | — |
| Sohn Catherine A.Director · 2 transactions | — | 1.5K | — | 1.5K | — |
| Jorkasky DianeDirector · 1 transaction | — | 527 | — | 527 | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 3 years: +85.2K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.